Journals / MN Oftalmoloji / 2005 / Cilt: 12 - Sayı: 2

A comparison of side effect profiles of latanoprost, travoprost and bimatoprost in primary open angle glaucoma patients

Primer açık açılı glokom olgularında latanoprost, travoprost ve bimatoprost'un yan etki profillerinin karşılaştırılması

Pages
113–117
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The other side effects were noted less frequently in all groups, differences between groups were not statistically significant.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate side effect profiles of latanaprost 0.005% (1.group), travoprost 0.004% (2.group), and bimatoprost 0.03% (3.group) in primary open angle glaucoma patients.
📊
Key Findings & Data:Side effects (drug intolerence, burning, itching, conjunctival hyperemia, eyelash growth, hypertrichosis, periocular pigmentation, darkening of the iris color) were noted at first week and 1st, 2th, 3th, 6th months.
💡
Conclusion & Impact:The other side effects were noted less frequently in all groups, differences between groups were not statistically significant.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kloprostenol · İlaç değerlendirmesi · Glokom

Abstract

Purpose: To evaluate side effect profiles of latanaprost 0.005% (1.group), travoprost 0.004% (2.group), and bimatoprost 0.03% (3.group) in primary open angle glaucoma patients. Material and Methods: Eighteen new drug user patients were randomized in each group. Antiglaucomatous medications were applied as one drop at night in all patients. Side effects (drug intolerence, burning, itching, conjunctival hyperemia, eyelash growth, hypertrichosis, periocular pigmentation, darkening of the iris color) were noted at first week and 1st, 2th, 3th, 6th months. Conjunctival hyperemia were scored as mild, moderete and severe. Paired t test, chi-square test, Mann-Whitney U tests were used for statistical evaluation. Statistical significance was accepted as p<0.05. Results: Conjunctival hyperemia were 38.9% in group 1, 58.8% in group 2 and 64.7% in group 3. Conjunctival hyperemia were the least frequent in the first group and the differences were statistically significant. Mean hyperemia scores were 0.61±0.8 in group 1, 1.2±1 in group 2 and 1.5±1.1 in group 3. Conjunctival hyperemia scores were also lowest in the first group and difference were statistically significant (p<0.05). Eyelash growth and hypertrichosis were more frequently encountered in the third group, but differences were not statistically significant (p>0.05). Considering all side effects, first group had lowest side effect frequency. Conclusion: All of three drugs were well-tolerated by the patients. However, lower and milder conjunctival hyperemia increases drug tolerence in the latanoprost group. The other side effects were noted less frequently in all groups, differences between groups were not statistically significant.

Özet

Amaç: Primer açık açılı glokom olgularında kullanılan latanoprost %0.005 (1. grup), travoprost %0.04 (2.grup) ve bimatoprost %0.03 (3.grup)'un yan etki profillerinin değerlendirilerek, grupların karşılaştırılması amaçlandı. Gereç ve Yöntem: Her grup için randomize olarak yeni tedavi başlanan 18'er olgu seçildi. Glokom tedavisi her üç grupta akşamları 1 damla şeklinde uygulandı. Olguların 1. hafta, 1, 3, 6. ay ve son kontrol muayeneleri yapılarak, belirlenen yan etkiler (ilaca tahammülsüzlük, yanma-batma, kaşıntı, konjonktival hiperemi, kirpiklerde uzama, hipertrikoz, göz çevresinde pigmentasyon, iris renginde koyulaşma) kaydedildi. Konjonktival hiperemi değerlendirmesi için skorlama yapıldı. Sonuçların istatistiksel değerlendirmesinde paired t test, ki kare testi ve Mann-Whitney U testi kullanıldı. İstatistiksel anlamlılık p 0.05). Üç grup görülen tüm yan etkiler açısından karşılaştırıldığında, 1. grubun en az yan etki profiline sahip olduğu sonucuna ulaşıldı. Sonuç: Her üç glokom ilacı da hastalar tarafından iyi tolere edilmektedir. Ancak latanoprost kullanan olgularda konjonktival hipereminin daha az ve daha hafif dereceli olması, hastanın verilen tedaviye uyumunu kolaylaştırmaktadır. Diğer yan etkiler daha az sıklıkta görülmekte ve gruplar arasında istatistiksel bir farklılık izlenmemektedir.

🔖

Cite This Article

SARICAOĞLU, M. S., KARAKURT, A., ŞENGÜN, A., HASIRİPİ, H., KARABULUT, E. (2005). A comparison of side effect profiles of latanoprost, travoprost and bimatoprost in primary open angle glaucoma patients. MN Oftalmoloji, Cilt: 12 - Sayı: 2, 113–117. https://ajindex.com/articles/296894

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002; 47 (suppl 1):53-64.
  2. Weinreb RN, Kashiwagi K, Kashiwagi F, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997; 38:2772-80.
  3. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Topical prostaglandin.F2a treatment reduces collagen types I, III, and IV in the monkey outflow pathway. Arch Ophthalmol 1999; 117:794-801. Brubaker RF. Mecanism of action of bimatoprost (Lumigan) Surv Ophthalmol 2001; 45 (suppl 4):347-51.
  4. Noruyama S, Sugimoto Y, Ushikubi F. Protanoid reseptors:structures, properties, and functions. Physiol Rev 1999; 79:1193-226.
  5. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol 2000; 11:112-5.
  6. Woodward DF, Krauss AHP, Chen J, et al. The pharmacology of bimatoprost (Lumigan) Surv Ophthalmol 2001;45(suppl4):337-45.
  7. Sharif NA, Williams GW, Kelly CR. Bimatoprost its free acid are prostaglandin FP reseptör agonists. Eur J Ophthalmol 2001;432:211-3.
  8. Matsuo T, Cynader MS. The EP2 reseptör is the predominant prostanoid reseptör in the human ciliary muscle. Br J Ophthalmol 1993; 77:110-4.
  9. Negishi M, Sugimoto Y, Ichikawa A. Molecular mechanisms of diverse actions of prostanoid reseptors. Biochem Biophys Acta 1995; 1259:109-19.
  10. Morgan PV, Proniuk S, Blanchard J, Noecker RJ. Effect of temparature and light on the stability of latanoprost and its clinical relevance. J Glaucoma 2001; 10:401-5.
  11. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six month randomised clinical trial comparing the intraocular pressure lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135:55-63.
  12. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost and travoprost in patients with elevated intraocular pressure: A 12 week randomised, masked evaluator multicenter study. Am J Ophthalmol 2003; 135:688-703. Stjern Schantz JW. From PGF2a isopropyl ester to latanoprost: a rewiew of the development of Xalatan. The proctor lecture. Invest Ophthalmol Vis Sci 2001; 42:1134-45.
  13. Netland PA, Landy T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84. Stewart